Caris Life Sciences vs Immunovant
Caris Life Sciences (CAI), health care, and Immunovant (IMVT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Immunovant is worth $6.9B on the stock market and Caris Life Sciences $5.7B: Immunovant is valued at 20% more. Over the past year Caris Life Sciences's share price has moved -11.6% and Immunovant's +40.5%.
Key facts
- Caris Life Sciences market value
- $5.7B
- Immunovant market value
- $6.9B
- Caris Life Sciences P/E
- 12.0
- Caris Life Sciences revenue
- $812MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Caris Life Sciences | Immunovant |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $5.7Blower | $6.9Bhigher |
| Revenue | $812M | — |
| Earnings | -$68.1Mhigher | -$505.6Mlower |
| Employees | 1,846higher | 315lower |
| Total assets | $1.1Bhigher | $957Mlower |
| Valuation | ||
| P/E | 12.0 | — |
| P/S | 7.0 | — |
| P/B | 8.9lower | 10.5higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 5.56% | — |
| Balance sheet | ||
| Net assets | $577.3Mlower | $852.6Mhigher |
| Total liabilities | $548.4Mhigher | $104.4Mlower |
| Total debt | $379M | — |
| Cash on hand | $796.3Mlower | $902.1Mhigher |
| Price change | ||
| Today | -5.05%lower | -0.21%higher |
| 1 year | -11.6%lower | +40.5%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Caris Life Sciences only (2)
Immunovant only (3)
- Andrew Spokes1.1%
- Julian and Felix Baker1.0%
- David Einhorn0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns CAI · Who owns IMVT
More on Caris Life Sciences
Further comparisons
Caris Life Sciences against its closest peers
Immunovant against its closest peers
Learn
Questions and answers
Which is bigger, Caris Life Sciences or Immunovant?
By market value, Immunovant is the larger: $6.9B against $5.7B for Caris Life Sciences.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Caris Life Sciences and Immunovant?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Caris Life Sciences and 3 hold Immunovant.
Cite this page
Funkfolio, “Caris Life Sciences vs Immunovant”, data as of 18 November 2026. https://funkfolio.com/compare/cai-vs-imvt
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.